Global patent index - EP 1037910 A2

EP 1037910 A2 2000-09-27 - MAINTENANCE OF SMOOTH MUSCLE INTEGRITY BY MORPHOGENIC PROTEINS

Title (en)

MAINTENANCE OF SMOOTH MUSCLE INTEGRITY BY MORPHOGENIC PROTEINS

Title (de)

NACHSCHUTZ DER GLATTE MUSKULATUR DURCH MORPHOGENETISCHE PROTEIN

Title (fr)

ENTRETIEN DE L'INTEGRITE DE MUSCLES LISSES A L'AIDE DE PROTEINES MORPHOGENIQUES

Publication

EP 1037910 A2 (EN)

Application

EP 98961838 A

Priority

  • US 9825398 W
  • US 6769097 P

Abstract (en)

[origin: WO9928341A2] Disclosed are compositions and methods for maintaining the integrity of smooth muscle, particularly vascular smooth muscle. Vascular diseases are characterized by an excessive build-up of vascular smooth muscle cells, resulting in an occlusion of a blood vessel, and/or by loss of elasticity in the blood vessels. Causes of blood vessel occlusion include smooth muscle cell proliferation and inflammatory responses. Inhibition of the proliferation of smooth muscle cells or inflammatory responses represents an effective treatment for vascular disorders, such as atherosclerosis and restenosis. Treatment may include administration of a morphogenic protein. The protein itself may be delivered to the site of vascular occlusion or the protein may be delivered by a vector, such as an adenoviral vector containing a DNA insert encoding a morphogenic protein. Such compositions and methods may also inhibit the responses of smooth muscle cells to various traumas, such as exposure to toxic agents. All of these treatmetns operate to preserve the cell phenotype by inhibiting an increase in extracellular matrix proteins, such as collagen, or by maintaining the normal balance of extracellular matrix proteins, such as Types I and III collagen.

IPC 1-7 (main, further and additional classification)

C07K 14/00

IPC 8 full level (invention and additional information)

A61K 38/18 (2006.01); C07K 14/47 (2006.01); C07K 14/51 (2006.01); A61K 38/00 (2006.01); A61K 48/00 (2006.01)

CPC (invention and additional information)

C07K 14/51 (2013.01); A61K 38/1875 (2013.01); C07K 14/4702 (2013.01); A61K 48/00 (2013.01)

Citation (search report)

See references of WO 9928341A3

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

EPO simple patent family

WO 9928341 A2 19990610; WO 9928341 A3 19990805; WO 9928341 A9 20010531; AU 1706499 A 19990616; CA 2314423 A1 19990610; EP 1037910 A2 20000927

INPADOC legal status

2003-12-03 [18D] DEEMED TO BE WITHDRAWN

- Ref Legal Event Code: 18D

- Effective date: 20030601

2001-06-27 [RAP1] TRANSFER OF RIGHTS OF AN EP PUBLISHED APPLICATION

- Owner name: CURIS, INC.

- Ref Legal Event Code: RAP1

2001-04-04 [RAP1] TRANSFER OF RIGHTS OF AN EP PUBLISHED APPLICATION

- Owner name: CREATIVE BIOMOLECULES, INC.

- Ref Legal Event Code: RAP1

2000-09-27 [17P] REQUEST FOR EXAMINATION FILED

- Ref Legal Event Code: 17P

- Effective date: 20000704

2000-09-27 [AK] DESIGNATED CONTRACTING STATES:

- Ref Legal Event Code: AK

- Designated State(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE